Journal
DRUG DISCOVERY TODAY
Volume 27, Issue 10, Pages -Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2022.07.010
Keywords
Statins; Angiogenesis; Vascularization; Cardiovascular; Ischemic heart disease
Categories
Ask authors/readers for more resources
This article discusses the impact of statins on angiogenesis, with a particular focus on angiogenesis in stroke and cardiovascular disease. Statins have pleiotropic effects, including both proangiogenic and antiangiogenic characteristics. These properties could offer new therapeutic applications.
Inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase by statins is affected by inhibiting the active site of the enzyme in a competitive manner. Statins reduce plasma cholesterol by inhibiting its de novo synthesis. In addition, statins impart 'pleiotropic' activities that do not directly relate to their ability to decrease cholesterol. The proangiogenic and antiangiogenic characteristics of statins are among these pleiotropic effects. These angiogenic-modifying properties could offer new therapeutic applications. Statins stimulate or suppress angiogenesis in a biphasic manner. Whereas low doses of statin stimulate angiogenesis, high doses reduce protein prenylation and limit cell development and angiogenesis. In this review, we discuss how statins impact angiogenesis, with a particular focus on angiogenesis in stroke and cardiovascular disease (CVD).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available